FARMEDIA AE - rizultati

Unjoni Ewropea - Iżlandiż - EMA (European Medicines Agency)

aservo equihaler

boehringer ingelheim vetmedica gmbh - ciclesonide - Öndunarfærum, Önnur lyf fyrir veikindi öndunarvegi sjúkdómum, inhalants - hestar - til að lina klínískum merki um alvarlega hrossum asma (áður þekktur sem endurtekinn Öndunarvegi – (rao), sumar haga tengslum endurtekin Öndunarvegi – (spa-rao)).

Unjoni Ewropea - Iżlandiż - EMA (European Medicines Agency)

recarbrio

merck sharp & dohme b.v. - imipenem einhýdrat, cílastatín járn, relebactam einhýdrat - gramm-neikvæð bakteríusýkingum - carbapenems, antibacterials for systemic use, - recarbrio is indicated for:- treatment of hospital-acquired pneumonia (hap), including ventilator associated pneumonia (vap), in adults (see sections 4. 4 og 5. - treatment of bacteraemia that occurs in association with, or is suspected to be associated with hap or vap, in adults. - treatment of infections due to aerobic gram-negative organisms in adults with limited treatment options (see sections 4. 2, 4. 4 og 5. Íhuga ætti að opinbera leiðsögn á réttri notkun af sýklalyfjum.

Unjoni Ewropea - Iżlandiż - EMA (European Medicines Agency)

pemetrexed baxter

baxter holding b.v. - pemetrexed disodium heptahydrate - carcinoma, non-small-cell lung; mesothelioma - Æxlishemjandi lyf - malignant pleural mesotheliomapemetrexed baxter in combination with cisplatin is indicated for the treatment of chemotherapy naïve patients with unresectable malignant pleural mesothelioma. non-small cell lung cancerpemetrexed baxter in combination with cisplatin is indicated for the first line treatment of patients with locally advanced or metastatic non-small cell lung cancer other than predominantly squamous cell histology (see section 5. pemetrexed baxter is indicated as monotherapy for the maintenance treatment of locally advanced or metastatic non-small cell lung cancer other than predominantly squamous cell histology in patients whose disease has not progressed immediately following platinum-based chemotherapy (see section 5. pemetrexed baxter is indicated as monotherapy for the second line treatment of patients with locally advanced or metastatic non-small cell lung cancer other than predominantly squamous cell histology (see section 5.